What is Small Pharma?
Small Pharma Inc. is a London-based biotechnology enterprise focused on the development of short-acting psychedelics designed to address complex mental health conditions. The company's core value proposition lies in its innovative pipeline, which includes the lead product candidate SPL026, currently undergoing Phase IIa clinical trials for the treatment of depressive disorder. Beyond its primary asset, the firm maintains a robust preclinical portfolio featuring tryptamine analogues such as SPL028 and SPL029, alongside SPL801, an oral formulation of 6-hydroxynorketamine. By prioritizing short-acting compounds, Small Pharma aims to improve the scalability and accessibility of psychedelic-assisted therapy, positioning itself as a key player in the evolving field of psychiatric innovation and neuro-regenerative medicine.
How much funding has Small Pharma raised?
Small Pharma has raised a total of $1.8M across 3 funding rounds:
Multiple Rounds
$1.8M
Private Equity (2017): $1M with participation from Angel CoFund
Grant (2017): $174K led by Angel CoFund
Other Financing Round (2017): $584K supported by Innovate UK
Key Investors in Small Pharma
Angel CoFund
Angel CoFund is a 100M GBP investment fund dedicated to supporting promising UK businesses through angel and co-investment, emphasizing capital growth and deep sector expertise.
Innovate UK
Innovate UK is a government-backed innovation agency that provides funding and support to businesses to drive research and development across various technological sectors.
What's next for Small Pharma?
With the recent strategic investment, Small Pharma is poised to advance its clinical roadmap, focusing heavily on the successful completion of its Phase IIa trials for SPL026. The company's strategic focus will likely shift toward optimizing its manufacturing processes and expanding its preclinical research into new tryptamine analogues. As the regulatory environment for psychedelic medicine continues to evolve, the firm is expected to leverage its current capital position to strengthen its intellectual property portfolio and potentially initiate partnerships that could facilitate broader market access. The focus remains on demonstrating clinical efficacy and safety, which will be paramount for future funding rounds and potential commercialization efforts in the global mental health market. Keywords: Small Pharma, biotechnology, mental health, psychedelic medicine, clinical trials, neuro-pharmacology, capital investment, drug development, therapeutic innovation.
See full Small Pharma company page
